Liver TET1 was found to promote metabolic dysfunction-associated steatotic liver disease (MASLD) by regulating CD36 expression, suggesting TET1 as a therapeutic target for MASLD treatment. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.